Biotech Stocks

. . . Comeback for silicon breast implants? The FDA gave conditional approval to Inamed (NasdaqNM:IMDC) to market silicon gel breast implants. In an approval letter, the FDA outlined conditions that must be met before the implants could be widely distributed in the U.S. Access to silicone-gel implants has been restricted in the U.S. since 1992. Since then, saline filled implants have been the standard, however many women and surgeons say that silicon implants are more natural-looking.

. . . Cheering the competition - When the FDA recently recommended the approval of Pfiizer's, Exubera, an inhaled insulin therapy and a competitor to Biosante's (Amex:BPA) product, Biosante cheered. Why so happy? In preclinical studies, Biosante's inhalable insulin delivery system has reported superior results. For Biosante's product, pulmonary insulin formulation offered about 60 percent absolute bioavailability. By comparison, the bioefficacy of the Exubera inhaled insulin is approximately 10 percent, according to data presented at a American Diabetic Association annual meeting.

From InvestingIN Biotech

More on biotech stocks